Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: IUD; Complications Clear all

Conditions: Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions: Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment; Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 7
States / cities: Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more

Conditions: Cardiovascular Diseases
Interventions: Not listed
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4,048 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Orange, California • Newark, Delaware • Chicago, Illinois + 9 more

Conditions: Vaginal Bleeding
Interventions: Intrauterine system; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Morristown, New Jersey • Newark, New Jersey

Conditions: Gestational Diabetes, Glucose Intolerance, Type 2 Diabetes, Intrauterine Contraception
Interventions: Mirena (Levonorgestrel IUD), Paragard (Copper IUD ) or Tubal Ligation; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: IUD, Abnormal Uterine Bleeding, Pain, Cervical
Interventions: Carevix, Tenaculum; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Intrauterine Fetal Demise
Interventions: Misoprostol; Drug
Lead sponsor: Gynuity Health Projects; Other
Eligibility: Female only
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Palo Alto, California • Newark, Delaware • Chicago, Illinois + 1 more

Conditions: Mucosal Inflammation, Contraceptive; Complications, Intrauterine
Interventions: Copper IUD, Etonogestrel implant, Levonorgestrel IUS, DMPA Sub-cutaneous; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Endometriosis
Interventions: norethindrone acetate (NETA), Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 13 Years to 24 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intrauterine Devices
Interventions: Intrauterine device; Device
Lead sponsor: Bayer; Industry
Eligibility: Up to 50 Years · Female only
Enrollment: 326,658 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Oakland, California • Pasadena, California • Indianapolis, Indiana + 1 more

Conditions: Adverse Pregnancy Outcome
Interventions: Lovenox 40mg; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Major Depressive Disorder, Miscarriage, Stillbirth, Neonatal Death
Interventions: Group Interpersonal Psychotherapy (IPT-G), Coping with Depression (CWD); Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Intrauterine Device (IUD), Abnormal Uterine Bleeding
Interventions: Carevix, Tenaculum; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions: Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System; Drug · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 18
States / cities: Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more

Conditions: Intrauterine Device Complications, Contraceptive Device Failure, IUD Fragmentation, Retained Intrauterine Device, Female Contraception, Women's Health, Reproductive Health
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 44 participants
Timeline: 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Fetal Growth Restriction (FGR), Placental Insufficiency, Preeclampsia, Still Births, Pregnancy, Pregnancy Complications, Pregnancy Outcomes, Ultrasound
Interventions: ultrafast power Doppler imaging (uPDI) / quantitative ultrasound (QUS); Device
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Complex Atypical Hyperplasia, Endometrial Cancer
Interventions: Metformin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Cincinnati, Ohio

Conditions: IUD Insertion Complication
Interventions: Ultrasound use; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: Female only
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
Interventions: Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program; Drug · Device · Behavioral
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 4
States / cities: Houston, Texas

Conditions: Lactation Suppressed
Interventions: Cabergoline 1 MG, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: San Jose, California • Stanford, California

Conditions: Lactation Suppressed
Interventions: Cabergoline 1 MG, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Circulating Cell Free Fetal DNA, Intrauterine Fetal Demise, Miscarriage
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions: Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally; Diagnostic Test · Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Stillbirth, Post-traumatic Stress Disorder, Anxiety, Depression
Interventions: Online Yoga + Facebook, Online Yoga; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Intrauterine Fetal Demise, Fetal Death
Interventions: Mifepristone, placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 16 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Continuation of the nuMoM2b Heart Health Study

Does Skyla Insertion Timing Impact Bleeding?

Postpartum Glucose Tolerance With Levonorgesterel IUD Use in Women With Recent Gestational Diabetes

Assessing Pain and Effectiveness of Carevix Device for IUD Insertions

Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy

Impact of Contraceptives on Cervico-Vaginal Mucosa

IUD and Norethindrone Acetate for Treatment of Endometriosis

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss

Suction Cervical Stabilizer Compared to Standard Tenaculum for Intrauterine Procedures

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

Patient Factors Associated With Fragmentation of Copper Intrauterine Device (IUD) Requiring Hysteroscopic Removal

Placental Imaging Techniques

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

Postplacental LNG-IUD Ultrasound Use Study

Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss

The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Feasibility of Online Yoga With Facebook After Stillbirth

Mifepristone Induction for Fetal Demise